Nebivolol (Bystolic®), a novel, highly cardioselective, third-generation β-blocker that recently received approval by the US FDA for the treatment of hypertension in the USA, is effective in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback